MDL Track
MDL 2846
S.D. Ohio
Bard/Davol polypropylene hernia mesh
23,695 pending
Medical Device · claims involving Bard and Davol polypropylene mesh failures, adhesion, migration, and revision surgery
Defendant
C.R. Bard, Inc.
MDL / Track
MDL 2846
S.D. Ohio
Judge
Judge Edmund A. Sargus, Jr.
Plaintiffs
roughly 23,736 pending (23,695 per JPML's March 2, 2026 report, plus 41 new filings tracked since)
Bellwether / Trial
Settlement Status
Track litigations for free. Save this matter, capture notes, and monitor live signals.
Case overview
MDL 2846 (In re: Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation) before Judge Edmund A. Sargus, Jr. in the S.D. Ohio entered active settlement administration after C.R. Bard and parent Becton, Dickinson and Company agreed in October 2024 to a global settlement framework exceeding $1 billion covering approximately 38,000 claims, with a Qualified Settlement Fund established December 16, 2024. Per the JPML's March 2, 2026 report, 23,695 claims remain pending; the court-appointed Intensive Settlement Process under Special Masters Ellen K. Reisman and John Jackson launches January 2027 for claims outside the main framework. Bellwether trials included Johns (defense verdict, July 2021), Milanesi ($255,000 plaintiff verdict on defective design, April 2022), Stinson ($500,000 plaintiff verdict on failure-to-warn, November 2023), and a $4.8 million state court verdict in Trevino v. Davol/Bard (R.I. 2022).
Causation Theory
Plaintiffs allege Bard's polypropylene hernia mesh products—including Ventralex ST, Ventralight ST, 3DMax, Perfix Plug, Sepramesh IP Composite, and Composix lines—degrade and shrink when permanently implanted, triggering chronic inflammatory responses that cause mesh migration, adhesion to bowel and bladder, bowel obstruction, enterocutaneous fistula, organ perforation, and chronic pain. Internal Bard documents produced in MDL 2846 discovery showed the company tracked polypropylene degradation risks, adverse events, and material failures years before litigation, with composite barrier layers allegedly degrading to expose underlying polypropylene to tissue. The Composix Kugel Mesh recall beginning in 2005 due to memory recoil ring breakage and bowel perforation risk underlies some of the earliest cases.
Case Management Orders
Litigation status
MDL 2846 remains active before Judge Edmund A. Sargus, Jr. in the S.D. Ohio with roughly 23,736 pending claims (23,695 per JPML's March 2, 2026 report, plus 41 new filings tracked since). A September 2026 Massachusetts Lawyers Weekly report flags an $88M verdict in the hernia mesh MDL. The court-appointed Intensive Settlement Process under Special Masters Ellen K. Reisman and John Jackson is scheduled to launch January 2027 for claims outside the October 2024 global settlement framework.
MDL Track
MDL 2846
S.D. Ohio
Bard/Davol polypropylene hernia mesh
23,695 pending
State Court Activity
15,000+ cases in Rhode Island state courts resolved under October 2024 settlement; Rhode Island remains active forum with favorable Anthony discovery rule jurisprudence
MDL 2846 Leadership
Plaintiff Leadership
Co-Lead Counsel
Timothy M. O'Brien
Levin Papantonio Thomas Mitchell Rafferty & Proctor, P.A.
tobrien@levinlaw.com850-435-7000Liaison Counsel
Executive Committee Chair
Executive Committee Member
Defense Leadership
Liaison Counsel
Geographic exposure
Approximately 38,000 claimants covered under October 2024 global settlement framework; ~23,695 actions remain pending in MDL 2846 as of March 2026. New filings continue in 2026 but face heightened pleading requirements under CMO #52. SOL windows vary 1-6 years by state with discovery rules controlling accrual; Rhode Island, Missouri, and North Dakota offer extended or favorable windows for late-discovered injuries.
MDL 2846 (In re: Davol Inc./C.R. Bard Hernia Mesh Products Liability Litigation) centralized before Judge Edmund A. Sargus, Jr.; 23,695 actions pending as of March 2026 per JPML report. Post-October 2024 settlement framework, new filings subject to CMO #52 (July 6, 2024) requiring 21-day SOL certification and 90-day causation expert reports.
RI Superior Court (Providence), No. PC-2018-9999: First major verdict $4.8 million to Paul Trevino (Ventralex bowel erosion, August 2022). Favorable Anthony discovery rule (677 A.2d 1036) maintains personal jurisdiction over C.R. Bard per Recine v. Davol Inc.; open to out-of-state plaintiffs with 3-year discovery-triggered SOL.
5-year discovery-triggered SOL per Mo. Rev. Stat. § 516.120; no statutory repose for product liability. Accrues upon discovery of injury and causal connection to Bard polypropylene mesh.
6-year discovery-triggered SOL per N.D. Cent. Code § 28-01-16; longest available period for delayed-manifestation Bard mesh injuries. Discovery rule applies; accrues upon discovery of injury and cause.
Key defendants
C.R. Bard, Inc.
Role: Manufacturer
Core defendant in MDL 2846. Global settlement announced October 2024; CMO #52 (July 6, 2024) imposed Lone Pine requirements and limited stay pending MSA implementation. New filings post-settlement face strict docket control and 14-day pharmacy/physician disclosure requirements.
Davol, Inc.
Role: Manufacturer
Bard subsidiary and co-defendant in MDL 2846. Jointly liable under settlement. Fourth bellwether (Bryan v. C.R. Bard, Inc., 2:18-cv-1440, S.D. Ohio Feb. 1, 2024) resulted in partial summary judgment grant; defense strategy emphasizes device-specific testing and learned intermediary doctrine.
| Defendant | Role | Intelligence Note |
|---|---|---|
| C.R. Bard, Inc. | Manufacturer | Core defendant in MDL 2846. Global settlement announced October 2024; CMO #52 (July 6, 2024) imposed Lone Pine requirements and limited stay pending MSA implementation. New filings post-settlement face strict docket control and 14-day pharmacy/physician disclosure requirements. |
| Davol, Inc. | Manufacturer | Bard subsidiary and co-defendant in MDL 2846. Jointly liable under settlement. Fourth bellwether (Bryan v. C.R. Bard, Inc., 2:18-cv-1440, S.D. Ohio Feb. 1, 2024) resulted in partial summary judgment grant; defense strategy emphasizes device-specific testing and learned intermediary doctrine. |
Timeline
MDL 2846 Formed in S.D. Ohio
Judicial Panel on Multidistrict Litigation consolidates federal Bard polypropylene hernia mesh cases in In re: Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation, MDL No. 2846, before Judge Edmund A. Sargus, Jr. in the Southern District of Ohio.
First Bellwether: Defense Verdict in Johns
Jury returns defense verdict for C.R. Bard in first MDL 2846 bellwether trial, Johns v. C.R. Bard, involving Ventralight ST mesh.
Second Bellwether: $255,000 Plaintiff Verdict
Jury awards $255,000 to plaintiff in Milanesi v. C.R. Bard on defective-design claim involving Ventralight ST mesh; $250,000 to Mr. Milanesi, $5,000 to Mrs. Milanesi.
Rhode Island State Court: $4.55 Million Trevino Verdict
Rhode Island state court jury awards $4.8 million in Trevino v. Davol/Bard; reduced to $4.55 million on post-trial motions. Verdict provides substantial settlement leverage.
Third Bellwether: $500,000 Plaintiff Verdict in Stinson
Jury awards $500,000 to plaintiff in Stinson v. Davol on failure-to-warn claim involving Perfix Plug; finds Bard liable for failure to warn doctors.
BD Announces Global Settlement Framework
Becton Dickinson announces settlement resolving nearly 25,000 federal MDL cases and more than 15,000 Rhode Island state court cases. BD discloses accruals of approximately $1.7 billion as of June 30, 2024. Terms confidential; no admission of liability.
Qualified Settlement Fund Established
Court approves Qualified Settlement Fund for MDL 2846; fund established to administer payments under tiered, points-based system keyed to injury severity, revision-surgery history, and documentation strength.
Special Masters Appointed for ISP
Court appoints Ellen K. Reisman and John Jackson as Special Masters to oversee Intensive Settlement Process (ISP) for remaining claims outside the main settlement framework.
23,382 Cases Remain Pending Per JPML
JPML report shows MDL 2846 holds 23,382 pending actions of 25,181 filed over its life, ranking among the largest active MDLs. Settlement administration continues alongside residual filings.
Statute of limitations
MDL 2846 global settlement announced October 2024; over 20,000 claims resolving. New filings post-July 6, 2024 face heightened pleading requirements per CMO #52: plaintiffs must certify under penalty of perjury within 21 days that claims are not time-barred and produce causation expert reports within 90 days. MDL proceedings do not toll state SOLs. Rhode Island state court remains active forum with favorable Anthony discovery rule jurisprudence; $4.8M verdict in Stinson case (August 2022). Judge Sargus imposed strict docket control measures; settlement payouts expected 2025-2026.
Rhode Island
3 years from discovery
Rule: Discovery rule applies per Anthony v. Abbott Labs, 677 A.2d 1036 (R.I. 1996); cause accrues when plaintiff knew or should have known of injury and its causal connection to the product
Discovery: Liberal discovery rule: statute runs from when victim discovers or reasonably should discover wrongdoing by manufacturer, not merely injury occurrence
RI Superior Court (Providence) maintains personal jurisdiction over C.R. Bard; favorable venue for out-of-state plaintiffs. See Recine v. Davol Inc.
⚠Ohio (MDL 2846)
2 years from discovery
Rule: Ohio Rev. Code § 2305.10(C); discovery rule applies for product liability claims
Discovery: Accrual upon discovery of injury and its causal link to the product
MDL 2846 (In re: Davol/C.R. Bard Hernia Mesh Prods. Liab. Litig.) centralized before Judge Edmund A. Sargus, Jr., S.D. Ohio. Post-July 6, 2024 filings subject to strict CMO #52 'Lone Pine' requirements: 14-day pharmacy/physician list, 21-day SOL certification under penalty of perjury, 90-day causation expert report. See CMO #52 (July 6, 2024)
Florida
4 years from discovery
Rule: Fla. Stat. § 95.11(3)(a), (e); discovery rule codified
Discovery: Accrues upon discovery of injury and reasonable connection to product
12-year statute of repose for products liability per § 95.031(2)(b) may bar older implants
Maine
6 years from discovery
Rule: 14 Me. Rev. Stat. Ann. § 752; longest SOL period for product liability
Discovery: Discovery rule applies; accrues upon discovery of injury and cause
Longest available SOL period; favorable for delayed-manifestation mesh injuries
Missouri
5 years from discovery
Rule: Mo. Rev. Stat. § 516.120; discovery rule applies for product liability
Discovery: Accrues upon discovery of injury and its causal connection to product
No statutory repose for product liability claims
North Dakota
6 years from discovery
Rule: N.D. Cent. Code § 28-01-16; longest SOL period for product liability
Discovery: Discovery rule applies; accrues upon discovery of injury and cause
6-year period matches Maine as longest available; favorable for delayed-manifestation cases
Minnesota
4 years from discovery
Rule: Minn. Stat. § 541.05; discovery rule applies for product liability
Discovery: Accrues upon discovery of injury and its causal connection
No statutory repose for product liability; 4-year period favorable for mesh cases
| State | SOL | Rule | Discovery Rule | Notes |
|---|---|---|---|---|
| Rhode Island | 3 years from discovery | Discovery rule applies per Anthony v. Abbott Labs, 677 A.2d 1036 (R.I. 1996); cause accrues when plaintiff knew or should have known of injury and its causal connection to the product | Liberal discovery rule: statute runs from when victim discovers or reasonably should discover wrongdoing by manufacturer, not merely injury occurrence | RI Superior Court (Providence) maintains personal jurisdiction over C.R. Bard; favorable venue for out-of-state plaintiffs. See Recine v. Davol Inc. |
| ⚠Ohio (MDL 2846) | 2 years from discovery | Ohio Rev. Code § 2305.10(C); discovery rule applies for product liability claims | Accrual upon discovery of injury and its causal link to the product | MDL 2846 (In re: Davol/C.R. Bard Hernia Mesh Prods. Liab. Litig.) centralized before Judge Edmund A. Sargus, Jr., S.D. Ohio. Post-July 6, 2024 filings subject to strict CMO #52 'Lone Pine' requirements: 14-day pharmacy/physician list, 21-day SOL certification under penalty of perjury, 90-day causation expert report. See CMO #52 (July 6, 2024) |
| Florida | 4 years from discovery | Fla. Stat. § 95.11(3)(a), (e); discovery rule codified | Accrues upon discovery of injury and reasonable connection to product | 12-year statute of repose for products liability per § 95.031(2)(b) may bar older implants |
| Maine | 6 years from discovery | 14 Me. Rev. Stat. Ann. § 752; longest SOL period for product liability | Discovery rule applies; accrues upon discovery of injury and cause | Longest available SOL period; favorable for delayed-manifestation mesh injuries |
| Missouri | 5 years from discovery | Mo. Rev. Stat. § 516.120; discovery rule applies for product liability | Accrues upon discovery of injury and its causal connection to product | No statutory repose for product liability claims |
| North Dakota | 6 years from discovery | N.D. Cent. Code § 28-01-16; longest SOL period for product liability | Discovery rule applies; accrues upon discovery of injury and cause | 6-year period matches Maine as longest available; favorable for delayed-manifestation cases |
| Minnesota | 4 years from discovery | Minn. Stat. § 541.05; discovery rule applies for product liability | Accrues upon discovery of injury and its causal connection | No statutory repose for product liability; 4-year period favorable for mesh cases |
Live intelligence
AI litigation brief
Bard Hernia Mesh remains established mass tort / active mdl with 70 current signals in the accepted feed.
Overview
MDL 2846 remains active before Judge Edmund A. Sargus, Jr. in the S.D. Ohio with roughly 23,736 pending claims (23,695 per JPML's March 2, 2026 report, plus 41 new filings tracked since). A September 2026 Massachusetts Lawyers Weekly report flags an $88M verdict in the hernia mesh MDL. The court-appointed Intensive Settlement Process under Special Masters Ellen K. Reisman and John Jackson is scheduled to launch January 2027 for claims outside the October 2024 global settlement framework.
Key developments
Trajectory
Court filings and press coverage are both active in MDL 2846, pointing to sustained litigation pressure rather than a one-off headline cycle. 6 live sources are contributing current context.
Editorial intelligence
MDL 2846 should stay on the lead docket watch because it is the primary consolidation vehicle for Bard Hernia Mesh.
Generated Sep 30, 2026, 10:00 AM UTC
70 events detected
Google News (10)
Lawyers set high bar with $88M verdict in hernia mesh MDL - Massachusetts Lawyers Weekly
Hernia Mesh Lawsuit Payout Guide (Updated Sep 2026) - LawFold.com
ONCA dismissed hernia mesh lawsuit, sets limitation clock - Canadian Lawyer
Hernia Mesh Lawsuit: Payouts & Deadlines (Aug 2026) - LawFold.com
After years of complications, some hernia mesh patients say payouts fall short - KIRO 7 News Seattle
Hernia Mesh Lawsuit Settlements (Updated August 2026) - LawFold.com
Etowah Co. couple awarded $88 million in landmark hernia mesh verdict - WBMA
Hernia Mesh Lawsuit: Settlement News & Who Qualifies - schmidtandclark.com
Hernia Mesh Lawsuit 2026: Payouts, Eligibility & Filing - lawfold.com
Judge approves surgical mesh class action in bid for compensation - BBC
Biomaterials advances • Zhang T • PMID 42748887 • Journal Article.
Materials (Basel, Switzerland) • Pashkouleva DL • PMID 42654523 • Journal Article.
Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation
PACER docket filed in JPML: The plaintiffs claim that Davol, Inc. and C.R. Bard, Inc. produced and sold defective hernia mesh devices, leading to injuries such as those related to the defective nature of the products. The involved products include 3DMax Mesh, Bard Mesh, Composix Kugel Hernia Patch, and Ventralex Hernia Patch,
Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation
PACER docket entry from OHSD: COMPLAINT with JURY DEMAND against All Defendants (Filing fee $ 405 paid), filed by JENNIFER COYNE. (Attachments: # 1 Civil Cover Sheet) (Martin, Ben) (Entered: 09/29/2026)
Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation
PACER docket entry from OHSD: COMPLAINT with JURY DEMAND against C.R. Bard Inc, Davol Inc ( Filing fee $ 405 paid - receipt number: AOHSDC-11253630), filed by Ronald Knight. (Attachments: # 1 Civil Cover Sheet) (Preston, A.) (Entered: 09/28/2026)
Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation
PACER docket entry from OHSD: COMPLAINT with JURY DEMAND against C.R. Bard Inc, Davol Inc ( Filing fee $ 405 paid - receipt number: AOHSDC-11253624), filed by Mary L. Smith. (Attachments: # 1 Civil Cover Sheet) (Preston, A.) (Entered: 09/28/2026)
Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation
PACER docket entry from OHSD: COMPLAINT with JURY DEMAND against C.R. Bard Inc, Davol Inc ( Filing fee $ 405 paid - receipt number: AOHSDC-11253616), filed by Charles D. Styles, Jr, Vicky Styles. (Attachments: # 1 Civil Cover Sheet) (Preston, A.) (Entered: 09/28/2026)
Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation
PACER docket entry from OHSD: COMPLAINT with JURY DEMAND against C.R. Bard Inc, Davol Inc ( Filing fee $ 405 paid - receipt number: AOHSDC-11253563), filed by Duane Zimmerman. (Attachments: # 1 Civil Cover Sheet) (Preston, A.) (Entered: 09/28/2026)
Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation
PACER docket entry from OHSD: COMPLAINT with JURY DEMAND against All Defendants ( Filing fee $ 405 paid - receipt number: AOHSDC-11253379), filed by Joshua Baird. (Attachments: # 1 Civil Cover Sheet) (Marlowe, Emily) (Entered: 09/28/2026)
Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation
PACER docket entry from OHSD: COMPLAINT with JURY DEMAND against C.R. Bard Inc, Davol Inc ( Filing fee $ 405 paid - receipt number: AOHSDC-11253047), filed by Jorge Perez. (Attachments: # 1 Civil Cover Sheet) (Preston, A.) (Entered: 09/28/2026)
Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation
PACER docket entry from OHSD: COMPLAINT with JURY DEMAND against C.R. Bard Inc, Davol Inc ( Filing fee $ 405 paid - receipt number: AOHSDC-11250918), filed by Kevin Watson, Sarah Watson. (Attachments: # 1 Civil Cover Sheet) (Preston, A.) (Entered: 09/25/2026)
Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation
PACER docket entry from OHSD: COMPLAINT with JURY DEMAND against C.R. Bard Inc, Davol Inc ( Filing fee $ 405 paid - receipt number: AOHSDC-11250912), filed by Deborah Jones. (Attachments: # 1 Civil Cover Sheet) (Preston, A.) (Entered: 09/25/2026)
Workbench
Sign in to save litigations, capture notes, and monitor live signals. Sign in for unlimited.
LexGenius Ranking
92Score
Court, news, and regulatory activity are elevated
Monitoring
Live
monitoring
Last: Sep 30, 2026, 10:00 AM UTC
Next: —
Source Monitoring
PACER
PACER
Google News
MAUDE
PubMed
Event feed
70
events detected
AI Brief
Bard Hernia Mesh remains established mass tort / active mdl with 70 current signals in the accepted feed.
Overview
MDL 2846 remains active before Judge Edmund A. Sargus, Jr. in the S.D. Ohio with roughly 23,736 pending claims (23,695 per JPML's March 2, 2026 report, plus 41 new filings tracked since). A September 2026 Massachusetts Lawyers Weekly report flags an $88M verdict in the hernia mesh MDL. The court-appointed Intensive Settlement Process under Special Masters Ellen K. Reisman and John Jackson is scheduled to launch January 2027 for claims outside the October 2024 global settlement framework.
Key developments
PACER court filing on Dec 31: Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation. ‖ Massachusetts Lawyers Weekly news on Sep 7: Lawyers set high bar with $88M verdict in hernia mesh MDL - Massachusetts Lawyers Weekly. ‖ MAUDE FDA alert on Aug 28: MAUDE Filing 50495385: Mesh - Ventralex. ‖ PubMed research on Sep 14: Stepwise surface engineering of polypropylene mesh with metal-phenolic-polysaccharide synergistically promoting abdominal wall repair..
Generated Sep 30, 2026, 10:00 AM UTC
Tracked MDLs
MDL 2846
S.D. Ohio
Bard/Davol polypropylene hernia mesh